Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | EP300 | Q09472 | 1/20 | 0.40 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28802548 | 0.81 | ATM (0.69) | ATMALDH1A1POLBCYP1A2L3MBTL1 | |
| SCHEMBL1127259 | 0.79 | ATM (1.00) | ATMALDH1A1POLBCYP1A2L3MBTL1 | |
| SCHEMBL29951332 | 0.74 | CYP2A6 (0.57) | ALDH1A1L3MBTL1CYP3A4CYP2A6CYP2E1 | |
| SCHEMBL950321 | 0.73 | ALDH1A1 (0.45) | ATMALDH1A1POLBCYP1A2L3MBTL1 | |
| SCHEMBL12349882 | 0.72 | CYP2A6 (0.59) | ALDH1A1CYP3A4CYP2A6CYP2E1HTT | |
| SCHEMBL30080798 | 0.72 | HTT (0.55) | ALDH1A1L3MBTL1CYP3A4CYP2A6CYP2E1 | |
| SCHEMBL28195188 | 0.72 | CYP2A6 (0.50) | ALDH1A1L3MBTL1CYP3A4CYP2A6CYP2E1 | |
| SCHEMBL9110239 | 0.72 | HTT (0.55) | ALDH1A1L3MBTL1CYP3A4CYP2A6CYP2E1 | |
| SCHEMBL950165 | 0.72 | ALDH1A1 (0.69) | ATMALDH1A1POLBCYP1A2L3MBTL1 | |
| SCHEMBL31310093 | 0.71 | CYP2A6 (0.46) | ALDH1A1L3MBTL1CYP3A4CYP2A6CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114878727-B | Method for determining hymexazol residues in tobacco | 合肥高尔生命健康科学研究院有限公司 | 2023-07-25 | — | — | CN | claimed |
| CN-114878727-A | Method for determining hymexazol residues in tobacco | 合肥高尔生命健康科学研究院有限公司 | 2022-08-09 | — | — | CN | claimed |
| CN-114878727-B | Method for determining hymexazol residues in tobacco | 合肥高尔生命健康科学研究院有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-114878727-A | Method for determining hymexazol residues in tobacco | 合肥高尔生命健康科学研究院有限公司 | 2022-08-09 | — | — | CN | disclosed |
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-10676484-B2 | Compositions and methods for treating leukemia | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | DANA FARBER CANCER INST INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | COLD SPRING HARBOR LABORATORY | 2018-08-09 | — | — | US | disclosed |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| WO-2013006596-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| US-20100203039-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION | 2010-08-12 | — | — | US | disclosed |
| US-7700624-B2 | 3-aminocyclopentanecrboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| CN-101341123-A | 3-aminocyclopentanecarboxamides as chemokine receptor modulators | INCYTE CORP (US) | 2009-01-07 | — | — | CN | disclosed |
| EP-1971576-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007072201-A2 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070149532-A1 | 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors | INCYTE CORPORATION | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10813939-B2 | Bromodomain inhibitor as adjuvant in cancer immunotherapy | BRDT, BRD4, BRD1 | ATM 444/4885ALDH1A1 2424/4885POLB 845/4885 |
| US-10407441-B2 | Compositions and methods for treating neoplasia, inflammatory disease and other disorders | BRPF3, EP300, BRD3 | ATM 2001/4885ALDH1A1 3670/4885POLB 249/4885 |
| US-10676484-B2 | Compositions and methods for treating leukemia | MCL1, ABL1, FLT3 | ATM 887/4885ALDH1A1 1723/4885POLB 1637/4885 |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | ATM 4547/4885ALDH1A1 2656/4885POLB 2987/4885 |
| US-20170360801-A1 | BROMODOMAIN INHIBITOR AS ADJUVANT IN CANCER IMMUNOTHERAPY | BRDT, BRD4, BRD1 | ATM 444/4885ALDH1A1 2424/4885POLB 845/4885 |
| US-20180222917-A1 | COMPOSITIONS AND METHODS FOR TREATING LEUKEMIA | MCL1, ABL1, FLT3 | ATM 887/4885ALDH1A1 1723/4885POLB 1637/4885 |
| US-20100203039-A1 | 3-AMINOCYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR5, ACKR3, CXCR3 | ATM 4666/4885ALDH1A1 1697/4885POLB 3655/4885 |
| US-20070149532-A1 | 3-Aminocyclopentanecarboxamides as Modulators of Chemokine Receptors | CCR5, CCR2, ACKR3 | ATM 4741/4885ALDH1A1 1714/4885POLB 3304/4885 |
| US-20200148702-A1 | COMPOSITIONS AND METHODS FOR TREATING NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS | BRPF3, EP300, BRD3 | ATM 2001/4885ALDH1A1 3670/4885POLB 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.